Millipore Sigma Vibrant Logo
 

mabf2155-100ug


101 Results Advanced Search  
Showing
Products (68)
Documents (33)
Site Content (0)

Narrow Your Results Use the filters below to refine your search

Document Type

  • (29)
  • (4)
Can't Find What You're Looking For?
Contact Customer Service

 

  • Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. 6648524

    A synthetic heptapeptide from the amino terminus of the beta chain in human fibrin was used as an antigen to produce monoclonal antibodies that bind to fibrin even in the presence of human fibrinogen at the concentration found in plasma. As expected, the antifibrin activity was inhibited by the peptide antigen but not by a control heptapeptide. In a chicken ex vivo circulatory model for fibrin detection, intravenously administered monoclonal antibodies bound to human fibrin-coated disks placed in an extracorporeal chamber. These findings may lead to better methods for identifying deep vein and coronary artery thrombi.
    Document Type:
    Reference
    Product Catalog Number:
    Multiple
    Product Catalog Name:
    Multiple

  • A rapid pro-hemostatic approach to overcome direct oral anticoagulants. 27455511

    Direct inhibitors of coagulation factor Xa (FXa) or thrombin are promising oral anticoagulants that are becoming widely adopted. The ability to reverse their anticoagulant effects is important when serious bleeding occurs or urgent medical procedures are needed. Here, using experimental mouse models of hemostasis, we show that a variant coagulation factor, FXa(I16L), rapidly restores hemostasis in the presence of the anticoagulant effects of these inhibitors. The ability of FXa(I16L) to reverse the anticoagulant effects of FXa inhibitor depends, at least in part, on the ability of the active site inhibitor to hinder antithrombin-dependent FXa inactivation, paradoxically allowing uninhibited FXa to persist in plasma. Because of its inherent catalytic activity, FXa(I16L) is more potent (by >50-fold) in the hemostasis models tested than a noncatalytic antidote that is currently in clinical development. FXa(I16L) also reduces the anticoagulant-associated bleeding in vivo that is induced by the thrombin inhibitor dabigatran. FXa(I16L) may be able to fill an important unmet clinical need for a rapid, pro-hemostatic agent to reverse the effects of several new anticoagulants.
    Document Type:
    Reference
    Product Catalog Number:
    Multiple
    Product Catalog Name:
    Multiple

  • Anti-Fibrin, clone 59D8 - 4047600

    Document Type:
    Certificate of Analysis
    Lot Number:
    4047600
    Product Catalog Number:
    MABS2155-100UG
    Product Catalog Name:
    Anti-Fibrin Antibody, clone 59D8

  • Anti-Fibrin, clone 59D8 - 3283176

    Document Type:
    Certificate of Analysis
    Lot Number:
    3283176
    Product Catalog Number:
    MABS2155-100UG
    Product Catalog Name:
    Anti-Fibrin Antibody, clone 59D8